JMML
MCID: LKM066
MIFTS: 60

Leukemia, Acute Myelomonocytic, Somatic, Somatic (JMML) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Aliases & Descriptions for Leukemia, Acute Myelomonocytic, Somatic, Somatic:

Name: Leukemia, Acute Myelomonocytic, Somatic, Somatic 54 38
Juvenile Myelomonocytic Leukemia 54 38 12 50 56 29 52 14 69
Leukemia, Juvenile Myelomonocytic 54 50 66 13
Jmml 50 56 66
Leukemia, Juvenile Myelomonocytic, Somatic 54
Juvenile Chronic Myelomonocytic Leukemia 56
Juvenile Chronic Myelogenous Leukemia 66
Leukemia, Myelomonocytic, Juvenile 42

Characteristics:

Orphanet epidemiological data:

56
juvenile myelomonocytic leukemia
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood,Infancy;

HPO:

32
leukemia, acute myelomonocytic, somatic, somatic:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 607785
Disease Ontology 12 DOID:0050458
ICD10 33 C93.3 C93.30
MeSH 42 D054429
NCIt 47 C9233
Orphanet 56 ORPHA86834
MESH via Orphanet 43 D054429
UMLS via Orphanet 70 C0349639
ICD10 via Orphanet 34 C93.3
UMLS 69 C0349639

Summaries for Leukemia, Acute Myelomonocytic, Somatic, Somatic

OMIM : 54 Juvenile myelomonocytic leukemia is an aggressive pediatric myelodysplastic syndrome (MDS)/myeloproliferative disorder... (607785) more...

MalaCards based summary : Leukemia, Acute Myelomonocytic, Somatic, Somatic, also known as juvenile myelomonocytic leukemia, is related to noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia and juvenile myelomonocytic leukemia, somatic arhgap26-related, and has symptoms including juvenile myelomonocytic leukemia, exanthema and fatigue. An important gene associated with Leukemia, Acute Myelomonocytic, Somatic, Somatic is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include lymph node, and related phenotypes are Decreased viability and growth/size/body region

UniProtKB/Swiss-Prot : 66 Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

Related Diseases for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Diseases related to Leukemia, Acute Myelomonocytic, Somatic, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Related Disease Score Top Affiliating Genes
1 noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 12.5
2 juvenile myelomonocytic leukemia, somatic arhgap26-related 12.1
3 juvenile myelomonocytic leukemia, somatic cbl-related 12.1
4 juvenile myelomonocytic leukemia, somatic nf1-related 12.1
5 juvenile myelomonocytic leukemia, somatic ptpn11-related 12.1
6 noonan syndrome 1 11.2
7 myelodysplastic myeloproliferative cancer 11.1
8 noonan syndrome 6 11.1
9 noonan syndrome 8 11.1
10 noonan syndrome 4 11.1
11 noonan syndrome 5 11.1
12 noonan syndrome 7 11.1
13 noonan syndrome 3 11.1
14 noonan syndrome 9 11.1
15 noonan syndrome 10 11.1
16 pseudomonas stutzeri infections 10.3 KRAS NRAS PTPN11
17 rdh12-related leber congenital amaurosis 10.3 KRAS NRAS PTPN11
18 erythrocyte lactate transporter defect 10.3 HRAS KRAS NRAS
19 melanocytic nevus syndrome, congenital, somatic 10.3 HRAS KRAS NRAS
20 syndactyly-polydactyly-earlobe syndrome 10.2 HRAS KRAS NF1 PTPN11
21 leukemia 10.2
22 kidney clear cell sarcoma 10.2 HRAS KRAS PDGFRA
23 hyperproinsulinemia 10.2 HRAS KRAS PTPN11
24 ossifying fibromyxoid tumor 10.2 HRAS KRAS NRAS
25 cardiomyopathy, dilated, 1r 10.2 NF1 PTPN11 SPRED1
26 skin epithelioid hemangioma 10.2 HRAS NF1 PTPN11
27 abdominal obesity-metabolic syndrome 10.2 PDGFRA RUNX1 SETBP1
28 malignant skin fibrous histiocytoma 10.2 HRAS KRAS
29 regional odontodysplasia 10.2 GATA2 SETBP1 TET2
30 spongiotic dermatitis 10.2 HRAS KRAS NRAS
31 unilateral hemispheric polymicrogyria 10.2 FLT3 RUNX1
32 agammaglobulinemia 8, autosomal dominant 10.2 FLT3 GATA2 KRAS
33 colorectal adenoma 10.2 FLT3 RUNX1 SETBP1 TET2
34 glomeruloid hemangioma 10.2 HRAS KRAS NF1 NRAS PTPN11
35 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 10.2 CBL DPM1 STAT5B
36 vascular hemostatic disease 10.2 HRAS KRAS PDGFRA
37 focal epilepsy 10.1 PDGFRA PTPN11 STAT5B TET2
38 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.1 DPM1 PDGFRA
39 erythrocytosis, somatic 10.1 DPM1 FLT3 PDGFRA TET2
40 seborrheic dermatitis 10.1 HRAS NF1 PDGFRA PTPN11 SPRED1
41 chromosome 15q11-q13 duplication syndrome 10.1 HRAS NF1 PTPN11 SHOC2 SPRED1
42 leopard syndrome 3 10.1 HRAS KRAS PTPN11 SHOC2 SPRED1
43 familial hyperaldosteronism 10.1 CBL FLT3 HRAS KRAS NRAS RUNX1
44 liver disease 10.1 CSF2 FLT3 MLLT11 NRAS PTPN11 RUNX1
45 neurotrophic keratoconjunctivitis 10.1 CSF2 CSF2RA GATA2
46 hyperparathyroidism, neonatal 10.0 CSF2 FLT3 GATA2 NRAS TET2
47 bleeding disorder, platelet-type, 18 10.0 FLT3 GATA2 NRAS RUNX1 STAT5B
48 hyperphosphatasia with mental retardation syndrome 2 10.0 FLT3 PDGFRA RUNX1
49 milker's nodule 10.0 CBL FLT3 HRAS NRAS PTPN11 RUNX1
50 metachondromatosis 10.0 HRAS KRAS NF1 NRAS PTPN11 SHOC2

Graphical network of the top 20 diseases related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:



Diseases related to Leukemia, Acute Myelomonocytic, Somatic, Somatic

Symptoms & Phenotypes for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Clinical features from OMIM:

607785

Human phenotypes related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 juvenile myelomonocytic leukemia 32 HP:0012209

UMLS symptoms related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:


exanthema, fatigue, fever

GenomeRNAi Phenotypes related to Leukemia, Acute Myelomonocytic, Somatic, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10 KRAS HRAS
2 Decreased viability GR00106-A-0 10 KRAS
3 Decreased viability GR00173-A 10 PDGFRA FLT3
4 Decreased viability GR00221-A-1 10 NF1 NRAS PDGFRA FLT3 HRAS KRAS
5 Decreased viability GR00221-A-2 10 NF1 HRAS KRAS
6 Decreased viability GR00221-A-3 10 NRAS PDGFRA HRAS
7 Decreased viability GR00221-A-4 10 NF1 PDGFRA FLT3
8 Decreased viability GR00301-A 10 KRAS
9 Decreased viability GR00381-A-1 10 KRAS
10 Decreased cell migration GR00055-A-1 9.55 ARHGAP26 CBL HRAS KRAS NF1
11 Increased cell migration GR00055-A-3 8.92 CBL HRAS KRAS NF1

MGI Mouse Phenotypes related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.42 CBL CSF2 FLT3 GATA2 HRAS KRAS
2 cardiovascular system MP:0005385 10.37 CBL CSF2 GATA2 HRAS KRAS NF1
3 endocrine/exocrine gland MP:0005379 10.37 STAT5B TET2 CBL CSF2 FLT3 GATA2
4 homeostasis/metabolism MP:0005376 10.37 STAT5B CBL CSF2 FLT3 GATA2 HRAS
5 cellular MP:0005384 10.36 RUNX1 STAT5B TET2 PDGFRA PTPN11 CBL
6 hematopoietic system MP:0005397 10.35 CBL CSF2 FLT3 GATA2 KRAS PDGFRA
7 behavior/neurological MP:0005386 10.34 CBL CSF2 DPM1 HRAS KRAS NF1
8 mortality/aging MP:0010768 10.34 DPM1 FLT3 GATA2 HRAS KRAS NF1
9 immune system MP:0005387 10.29 CBL CSF2 FLT3 KRAS NF1 NRAS
10 integument MP:0010771 10.24 CBL CSF2 HRAS KRAS NF1 NRAS
11 craniofacial MP:0005382 10.23 KRAS NF1 NRAS PDGFRA PTPN11 SPRED1
12 embryo MP:0005380 10.22 CSF2 GATA2 KRAS NF1 NRAS PDGFRA
13 liver/biliary system MP:0005370 10.11 CBL GATA2 KRAS NF1 NRAS PTPN11
14 neoplasm MP:0002006 10.1 CSF2 FLT3 HRAS KRAS NF1 NRAS
15 normal MP:0002873 10.06 GATA2 HRAS KRAS NF1 NRAS PDGFRA
16 limbs/digits/tail MP:0005371 10.02 KRAS NF1 NRAS PDGFRA PTPN11 SPRED1
17 no phenotypic analysis MP:0003012 9.97 FLT3 HRAS KRAS NRAS PDGFRA PTPN11
18 renal/urinary system MP:0005367 9.76 CSF2 GATA2 HRAS KRAS NF1 PDGFRA
19 pigmentation MP:0001186 9.73 CBL KRAS NF1 NRAS PDGFRA PTPN11
20 respiratory system MP:0005388 9.65 CBL CSF2 RUNX1 SHOC2 SPRED1 HRAS
21 skeleton MP:0005390 9.28 RUNX1 CBL CSF2 FLT3 HRAS KRAS

Drugs & Therapeutics for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Drugs for Leukemia, Acute Myelomonocytic, Somatic, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
7
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
8
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
11
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
12
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
13
Daunorubicin Approved Phase 3 20830-81-3 30323
14
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
15
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
16
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
17
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
18
Thioguanine Approved Phase 3 154-42-7 2723601
19
Asparaginase Approved Phase 3 9015-68-3
20
Lorazepam Approved Phase 3 846-49-1 3958
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
23
Butyric Acid Experimental Phase 3 107-92-6 264
24 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 3,Phase 2,Phase 1
27 Vitamin B Complex Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 6-Mercaptopurine Phase 3
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1
36 Acyclovir Phase 3
37 valacyclovir Phase 3
38 Muromonab-CD3 Phase 3,Phase 2
39 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
40 Cortisol succinate Phase 3
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Hydrocortisone 17-butyrate 21-propionate Phase 3
43 Hydrocortisone acetate Phase 3
44 Hydrocortisone-17-butyrate Phase 3
45 Etoposide phosphate Phase 3,Phase 2,Phase 1
46 Immunoglobulins Phase 3,Phase 2
47 Antibodies Phase 3,Phase 2
48 Bone Density Conservation Agents Phase 3
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
50 Calcium, Dietary Phase 3

Interventional clinical trials:

(show top 50) (show all 114)
id Name Status NCT ID Phase
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
2 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3
3 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
4 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
5 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
6 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
7 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
10 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
11 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
12 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3
13 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
14 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3
15 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2
16 Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia Completed NCT00025038 Phase 2
17 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Completed NCT01036009 Phase 2
18 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
19 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
20 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
21 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2
22 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2
23 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2
24 T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia Completed NCT00002718 Phase 2
25 Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer Completed NCT00126477 Phase 2
26 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease Completed NCT00003913 Phase 2
27 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00054327 Phase 2
28 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer Completed NCT00014469 Phase 2
29 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2
30 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2
31 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2
32 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2
33 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2
34 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2
35 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2
36 Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease Completed NCT00118326 Phase 1, Phase 2
37 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2
38 Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) Recruiting NCT02447666 Phase 2
39 Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) Recruiting NCT00167219 Phase 1, Phase 2
40 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2
41 Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies Recruiting NCT02120157 Phase 2
42 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Recruiting NCT02996773 Phase 1, Phase 2
43 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2
44 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2
45 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting NCT02790515 Phase 2
46 Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Recruiting NCT00309842 Phase 2
47 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Active, not recruiting NCT01824693 Phase 2
48 Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Active, not recruiting NCT02458235 Phase 2
49 Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Active, not recruiting NCT02333058 Phase 2
50 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2

Search NIH Clinical Center for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Leukemia, Acute Myelomonocytic, Somatic, Somatic:
Hemacord
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244

Cochrane evidence based reviews: leukemia, myelomonocytic, juvenile

Genetic Tests for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Genetic tests related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:

id Genetic test Affiliating Genes
1 Juvenile Myelomonocytic Leukemia 29

Anatomical Context for Leukemia, Acute Myelomonocytic, Somatic, Somatic

MalaCards organs/tissues related to Leukemia, Acute Myelomonocytic, Somatic, Somatic:

39
Lymph Node

Publications for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Variations for Leukemia, Acute Myelomonocytic, Somatic, Somatic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myelomonocytic, Somatic, Somatic:

66 (show all 18)
id Symbol AA change Variation ID SNP ID
1 ARHGAP26 p.Asn417Ser VAR_013623 rs121918546
2 KRAS p.Gly12Asp VAR_016026 rs121913529
3 KRAS p.Gly12Ser VAR_016028 rs121913530
4 KRAS p.Gly13Asp VAR_016029 rs112445441
5 NRAS p.Gly13Asp VAR_063084 rs121434596
6 NRAS p.Gly12Asp VAR_071129 rs121913237
7 PTPN11 p.Asp61Val VAR_015991 rs121918461
8 PTPN11 p.Asp61Tyr VAR_015992
9 PTPN11 p.Glu69Lys VAR_015993
10 PTPN11 p.Ala72Thr VAR_015996 rs121918453
11 PTPN11 p.Ala72Val VAR_015997 rs121918454
12 PTPN11 p.Glu76Ala VAR_015998 rs121918465
13 PTPN11 p.Glu76Gly VAR_015999 rs121918465
14 PTPN11 p.Glu76Lys VAR_016000 rs28933388
15 PTPN11 p.Glu76Val VAR_016001 rs121918465
16 PTPN11 p.Gly507Ala VAR_016002 rs397507546
17 PTPN11 p.Gly507Arg VAR_016003 rs397507545
18 SETBP1 p.Asp868Asn VAR_063807 rs267607042

ClinVar genetic disease variations for Leukemia, Acute Myelomonocytic, Somatic, Somatic:

6 (show all 19)
id Gene Variation Type Significance SNP ID Assembly Location
1 NF1 NM_000267.3(NF1): c.4614G> A (p.Trp1538Ter) single nucleotide variant Pathogenic rs137854555 GRCh37 Chromosome 17, 29588828: 29588828
2 NF1 NF1, IVS34, G-A, +18 single nucleotide variant Pathogenic
3 NF1 NM_000267.3(NF1): c.1642-8A> G single nucleotide variant Pathogenic rs267606602 GRCh37 Chromosome 17, 29548860: 29548860
4 ARHGAP26 NM_015071.5(ARHGAP26): c.1250A> G (p.Asn417Ser) single nucleotide variant Pathogenic rs121918546 GRCh37 Chromosome 5, 142421420: 142421420
5 ARHGAP26 ARHGAP26, 52-BP INS insertion Pathogenic
6 ARHGAP26 ARHGAP26, 74-BP INS insertion Pathogenic
7 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
8 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
9 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
11 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
12 PTPN11 NM_002834.4(PTPN11): c.227A> T (p.Glu76Val) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
13 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
14 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
15 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
16 CBL NM_005188.3(CBL): c.1112A> G (p.Tyr371Cys) single nucleotide variant Pathogenic rs387906666 GRCh37 Chromosome 11, 119148892: 119148892
17 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
18 CBL NM_005188.3(CBL): c.1228-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs727504426 GRCh37 Chromosome 11, 119149218: 119149218
19 PTPN11 NM_002834.4(PTPN11): c.181G> T (p.Asp61Tyr) single nucleotide variant Pathogenic rs397507510 GRCh37 Chromosome 12, 112888165: 112888165

Expression for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Search GEO for disease gene expression data for Leukemia, Acute Myelomonocytic, Somatic, Somatic.

Pathways for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Pathways related to Leukemia, Acute Myelomonocytic, Somatic, Somatic according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CBL CSF2 CSF2RA FLT3 HRAS KRAS
2
Show member pathways
13.93 CBL CSF2 CSF2RA FLT3 HRAS KRAS
3
Show member pathways
13.79 CBL CSF2RA HRAS KRAS NF1 NRAS
4
Show member pathways
13.6 CBL FLT3 HRAS KRAS NRAS PDGFRA
5
Show member pathways
13.58 CSF2 CSF2RA HRAS KRAS NF1 NRAS
6
Show member pathways
13.48 CSF2 CSF2RA FLT3 HRAS KRAS NRAS
7
Show member pathways
13.37 CSF2 CSF2RA GATA2 HRAS KRAS NRAS
8
Show member pathways
13.36 CSF2 CSF2RA HRAS KRAS NRAS PDGFRA
9
Show member pathways
13.1 CBL HRAS KRAS NF1 NRAS PDGFRA
10
Show member pathways
13.04 CBL CSF2 CSF2RA FLT3 HRAS KRAS
11
Show member pathways
12.85 CBL HRAS KRAS NRAS STAT5B
12
Show member pathways
12.85 CBL HRAS KRAS NRAS PTPN11
13
Show member pathways
12.84 CBL HRAS KRAS NRAS STAT5B
14
Show member pathways
12.84 CBL HRAS KRAS PTPN11 STAT5B
15
Show member pathways
12.8 CBL HRAS KRAS NRAS PDGFRA PTPN11
16 12.77 HRAS KRAS NF1 NRAS PDGFRA
17
Show member pathways
12.73 HRAS KRAS NF1 NRAS PDGFRA PTPN11
18
Show member pathways
12.66 HRAS KRAS NRAS PDGFRA PTPN11 STAT5B
19
Show member pathways
12.65 CBL CSF2 HRAS KRAS NRAS PTPN11
20
Show member pathways
12.64 CBL HRAS KRAS NRAS PTPN11 SPRED1
21
Show member pathways
12.56 CBL CSF2 HRAS KRAS NRAS PTPN11
22
Show member pathways
12.51 CBL HRAS KRAS NRAS PTPN11 STAT5B
23
Show member pathways
12.49 HRAS KRAS NRAS PDGFRA
24
Show member pathways
12.49 HRAS KRAS NRAS PDGFRA PTPN11
25
Show member pathways
12.48 CBL FLT3 HRAS KRAS NRAS PTPN11
26
Show member pathways
12.46 CBL HRAS KRAS NRAS PTPN11
27
Show member pathways
12.46 CBL CSF2 HRAS KRAS NRAS PTPN11
28
Show member pathways
12.45 HRAS KRAS NRAS PDGFRA
29
Show member pathways
12.45 HRAS KRAS NF1 PTPN11
30
Show member pathways
12.44 CBL HRAS PTPN11 STAT5B
31 12.44 CSF2 HRAS KRAS NRAS PDGFRA STAT5B
32
Show member pathways
12.43 CBL HRAS KRAS NRAS PTPN11
33
Show member pathways
12.39 CBL HRAS KRAS NRAS PTPN11
34
Show member pathways
12.38 CBL HRAS KRAS NRAS STAT5B
35 12.36 CBL HRAS KRAS NRAS PTPN11
36
Show member pathways
12.35 HRAS KRAS NF1 NRAS
37 12.35 HRAS KRAS NRAS STAT5B
38
Show member pathways
12.32 CBL FLT3 HRAS KRAS NRAS STAT5B
39
Show member pathways
12.29 HRAS KRAS NRAS PTPN11
40 12.28 HRAS KRAS NRAS PTPN11
41
Show member pathways
12.28 CSF2 CSF2RA HRAS PTPN11 STAT5B
42
Show member pathways
12.27 CBL HRAS KRAS NRAS PTPN11 STAT5B
43
Show member pathways
12.26 CBL HRAS KRAS NRAS PTPN11 SPRED1
44 12.24 CBL HRAS KRAS PTPN11 STAT5B
45
Show member pathways
12.23 HRAS KRAS NRAS STAT5B
46
Show member pathways
12.23 CBL HRAS PTPN11 SPRED1 STAT5B
47
Show member pathways
12.22 CBL FLT3 HRAS KRAS NRAS RUNX1
48 12.18 CBL FLT3 PDGFRA SPRED1
49
Show member pathways
12.16 HRAS KRAS NF1 NRAS
50
Show member pathways
12.11 CBL HRAS KRAS NRAS PDGFRA PTPN11

GO Terms for Leukemia, Acute Myelomonocytic, Somatic, Somatic

Cellular components related to Leukemia, Acute Myelomonocytic, Somatic, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 CBL DPM1 FLT3 GATA2 HRAS MLLT11
2 cytosol GO:0005829 9.44 ARHGAP26 CBL FLT3 HRAS KRAS MLLT11

Biological processes related to Leukemia, Acute Myelomonocytic, Somatic, Somatic according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 CSF2 FLT3 HRAS KRAS PDGFRA STAT5B
2 leukocyte migration GO:0050900 9.91 HRAS KRAS NRAS PTPN11
3 axon guidance GO:0007411 9.88 HRAS KRAS NRAS PTPN11
4 cytokine-mediated signaling pathway GO:0019221 9.84 CSF2RA FLT3 KRAS STAT5B
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 CBL FLT3 PDGFRA
6 positive regulation of MAP kinase activity GO:0043406 9.75 FLT3 HRAS KRAS
7 fibroblast growth factor receptor signaling pathway GO:0008543 9.71 CBL PTPN11 SHOC2 SPRED1
8 cellular response to epidermal growth factor stimulus GO:0071364 9.7 CBL PTPN11 STAT5B
9 positive regulation of DNA replication GO:0045740 9.69 CSF2 HRAS PDGFRA
10 ERBB2 signaling pathway GO:0038128 9.67 HRAS KRAS NRAS
11 hemopoiesis GO:0030097 9.67 FLT3 GATA2 RUNX1 TET2
12 peptidyl-tyrosine phosphorylation GO:0018108 9.65 CSF2 CSF2RA FLT3 PDGFRA STAT5B
13 homeostasis of number of cells within a tissue GO:0048873 9.63 GATA2 KRAS PTPN11
14 regulation of synaptic transmission, GABAergic GO:0032228 9.62 KRAS NF1
15 dendritic cell differentiation GO:0097028 9.61 CSF2 FLT3
16 response to isolation stress GO:0035900 9.6 HRAS KRAS
17 myeloid progenitor cell differentiation GO:0002318 9.57 FLT3 TET2
18 luteinization GO:0001553 9.56 PDGFRA STAT5B
19 Ras protein signal transduction GO:0007265 9.55 HRAS KRAS NF1 NRAS SHOC2
20 regulation of long-term neuronal synaptic plasticity GO:0048169 9.5 HRAS KRAS NF1
21 forebrain astrocyte development GO:0021897 9.43 KRAS NF1
22 epidermal growth factor receptor signaling pathway GO:0007173 9.35 CBL HRAS KRAS NRAS PTPN11
23 MAPK cascade GO:0000165 9.23 CSF2 CSF2RA HRAS KRAS NF1 NRAS
24 positive regulation of GTPase activity GO:0043547 10.02 ARHGAP26 CSF2 CSF2RA HRAS NF1 PDGFRA

Molecular functions related to Leukemia, Acute Myelomonocytic, Somatic, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ARHGAP26 CBL CSF2 CSF2RA DPM1 FLT3
2 protein complex binding GO:0032403 9.62 FLT3 KRAS NRAS PDGFRA
3 glucocorticoid receptor binding GO:0035259 9.37 FLT3 STAT5B
4 protein tyrosine kinase binding GO:1990782 9.26 CBL PTPN11
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.16 FLT3 PDGFRA
6 protein tyrosine kinase activity GO:0004713 9.02 CSF2 CSF2RA FLT3 PDGFRA STAT5B

Sources for Leukemia, Acute Myelomonocytic, Somatic, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....